Case Study: Market intelligence, Women’s Health, IVD
The Client
ARCEDI Biotech developed a novel method to separate rare fetal cells from the maternal bloodstream, enabling the detection of subtle genetic changes early in pregnancy. Powered by recent advances in DNA sequencing, this approach holds the potential to replace invasive and non-invasive prenatal testing methods.
The Challenge
ARCEDI engaged Chrysalis to assess the market potential for their cbNIPT (cell-based Non-Invasive Prenatal Testing) technology and develop a commercial and operational strategy to increase their valuation ahead of acquisition discussions.
Our Approach
To avoid potential valuation traps and prepare for commercial launch, Chrysalis delivered a three-pronged strategy:
KOL Input: Engage key opinion leaders to validate clinical relevance
Product Readiness: Evaluate technology maturity and market fit
Build Strategy: Define go-to-market and positioning roadmap
Critical Questions
- How would this innovation change clinical workflows?
- What is the revenue potential across priority markets?
- What markets should be entered first — and why?
- What competitive or adjacent technologies might pose a threat?
- Who are the right partners to scale and validate cbNIPT?
- How does this technology disrupt or complement current non-invasive techniques?
The Results
Chrysalis delivered a clear, co-developed view of market sizing, growth trajectory, and commercialization potential. We:
- Refined product concept and pricing
- Developed initial clinical development pathways
- Mapped commercial and operational roadmaps
- Identified strategic partners for scale-up
ARCEDI used these insights to actively engage in high-level acquisition discussions.
Testimonial
Testimony
“As a European-based prenatal diagnostics company, we engaged Chrysalis to define our strategy for establishing a novel prenatal test in the U.S. market. Chrysalis brought deep expertise across the prenatal diagnostics landscape and quickly clarified a complex environment. Their insights significantly de-risked our evaluation and strengthened future decision-making.”